Lakefront Biotherapeutics NV (STU:GXE) Cyclically Adjusted PS Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:GXE Lakefront Biotherapeutics NV STU:GXE
50 GF Score
Price €24.80
GF Value €99.65
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Lakefront Biotherapeutics NV Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Lakefront Biotherapeutics NV  (STU:GXE) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Lakefront Biotherapeutics NV Cyclically Adjusted PS Ratio Related Terms


Lakefront Biotherapeutics NV Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Lakefront Biotherapeutics NV's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lakefront Biotherapeutics NV Cyclically Adjusted PS Ratio Chart

Lakefront Biotherapeutics NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.67 7.14 6.22 4.17 3.55

Lakefront Biotherapeutics NV Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.75 4.24 3.40 3.12 3.12

STU:GXE vs VRTX, REGN, MRNA: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Lakefront Biotherapeutics NV's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lakefront Biotherapeutics NV Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lakefront Biotherapeutics NV's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Lakefront Biotherapeutics NV's Cyclically Adjusted PS Ratio falls into.


STU:GXE
50GF Score
Lakefront Biotherapeutics NV STU:GXE
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lakefront Biotherapeutics NV Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Lakefront Biotherapeutics NV's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Lakefront Biotherapeutics NV's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.173/138.0500*138.0500
=0.173

Current CPI (Jun. 2026) = 138.0500.

Lakefront Biotherapeutics NV Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.622 102.267 0.840
201609 0.243 102.118 0.329
201612 1.679 102.614 2.259
201703 0.703 103.972 0.933
201706 0.559 103.902 0.743
201709 0.529 104.170 0.701
201712 0.770 104.804 1.014
201803 0.744 105.419 0.974
201806 0.968 106.063 1.260
201809 1.747 106.618 2.262
201812 1.920 107.252 2.471
201903 0.605 107.876 0.774
201906 1.071 107.896 1.370
201909 10.582 107.470 13.593
201912 1.844 108.065 2.356
202003 1.466 108.550 1.864
202006 1.526 108.540 1.941
202009 1.952 108.441 2.485
202012 2.209 108.511 2.810
202103 1.741 109.522 2.194
202106 2.133 110.305 2.670
202109 0.980 111.543 1.213
202112 2.547 114.705 3.065
202203 2.077 118.620 2.417
202206 2.094 120.948 2.390
202209 2.069 124.120 2.301
202212 1.445 126.578 1.576
202303 0.889 126.528 0.970
202306 0.911 125.973 0.998
202309 0.928 127.083 1.008
202403 0.947 130.552 1.001
202406 1.182 130.691 1.249
202409 0.908 130.968 0.957
202412 1.146 132.346 1.195
202503 1.138 134.348 1.169
202506 0.991 133.495 1.025
202509 1.080 133.740 1.115
202512 13.670 135.080 13.971
202603 0.098 136.570 0.099
202606 0.173 138.050 0.173

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Lakefront Biotherapeutics NV (STU:GXE) Overvalued in 2026?

Based on GuruFocus' analysis, Lakefront Biotherapeutics NV stock appears to be undervalued. The current stock price of €24.80 is trading 75.1% below its estimated GF Value™ of €99.65. GuruFocus considers Lakefront Biotherapeutics NV to be Possible Value Trap.

Key valuation signals for STU:GXE:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €99.65 vs. price of €24.80 (75.1% below fair value)
  • GF Score™: 50/100 with 4 warning signs

No single metric tells the full story. See the STU:GXE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lakefront Biotherapeutics NV Business Description

Address Schalienhoevedreef 20 T, Mechelen, BEL, 2800
Lakefront Biotherapeutics NV a biopharmaceutical company committed to improving the lives of people with severe diseases. It focuses on delivering medicines with transformational impact for patients by accelerating life-changing science and innovation in areas of high unmet need. Its pipelines includes GLPG3667, GLPG5101, and GLPG5301.
50GF Score

Get the complete analysis for STU:GXE

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€24.80
Price
€99.65
GF Value